GlassScriptPhysician profile
Annalysa M Johnson
NPI 1306101282
$5,617.52
in general payments reported to CMS, 2019-2025
28 companies · $3,584 in 2025
The $3,584 reported for 2025 was more than what 96% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $70.33 · 2021: $395 · 2022: $562 · 2023: $492 · 2024: $244 · 2025: $3,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,161 · Travel and Lodging: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,161.48 |
| Travel and Lodging | $159.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,261.00 | 2025 | |
| Abbvie INC. | $599.01 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $276.34 | 2021-2025 | |
| Daiichi Sankyo INC. | $227.43 | 2019-2023 | Injectafer |
| Astellas Pharma US INC | $167.41 | 2022-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $149.00 | 2020-2025 | Slynd |
| Sage Therapeutics, LLC | $145.87 | 2024-2025 | Zurzuvae |
| Boston Scientific Corporation | $82.67 | 2025 | General - Female Sui |
| Myovant Sciences INC. | $80.78 | 2021-2022 | |
| Therapeuticsmd, INC. | $67.82 | 2019-2022 | |
| Urovant Sciences INC | $67.69 | 2022 | |
| Aspira Women'S Health INC | $63.78 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $61.28 | 2019-2021 | |
| Roche Diagnostics Corporation | $47.36 | 2019-2021 | |
| Channel Medsystems, INC. | $46.48 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $43.44 | 2024-2025 | Intrarosa |
| Mylan Pharmaceuticals INC. | $24.28 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $23.41 | 2019 | |
| Sanofi Pasteur INC. | $22.31 | 2024 | |
| Sumitomo Pharma America, INC. | $21.94 | 2023 | Myfembree |
| Organon LLC | $20.92 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.97 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.22 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $18.27 | 2021 | |
| Pfizer INC. | $18.03 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.83 | 2019 | |
| Shield Therapeutics INC | $14.43 | 2024 | |
| Minerva Surgical, INC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annalysa Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.